Journal of Clinical and Aesthetic Dermatology

FEB 2018

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/934167

Contents of this Issue

Navigation

Page 15 of 62

R A IMPORTANT SAFETY INFORMATION SERNIVO Spray can produce reversible hypothalamic-pituitary-adrenal manifest as Cushing's syndrome, hyperglycemia or unmasking of latent diabetes mellitus, and glucosuria. These events are rare and site. Do not use with occlusive dressings. Avoid use on the face, scalp, axilla, groin or other intertriginous areas. Use of SERNIVO Spray is atrophy are more likely to occur with occlusive use, prolonged use, or SERNIVO Spray. To report SUSPECTED SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at 1-800-FDA-1088. References: 1. to deliver and retain steroid in layers of skin associated with psoriasis. Poster presented at Winter Clinical, Koloa, HI, January 15-20, 2016. 2. Promius Pharma, LLC. Princeton, NJ. February 2016. 3. Gold LS, Jackson JM, Knuckles MLF, Weiss JS. Improvement in extensive moderate plaque psoriasis with a novel emollient spray J Drugs Dermatol. 2016;15(3):334-342. 4. Zirwas M, Hebert A. Fast relief of itching in psoriasis with DFD-01, a novel medium- at Winter Clinical, Kona, HI, January 13-18, 2017. 5. Kircik L, Bagel J. DFD-01, a novel plaque psoriasis on knees and elbows. Poster presented at Winter Clinical, Koloa, HI, January 15-20, 2016. SERNIVO is a registered trademark of Promius Pharma, LLC. © 2017 Promius Pharma, LLC. All rights reserved. SER-0417-097 April 2017 a 1 b 3 c since their last visit. 4 d SPRAY ON SERNIVO SPRAY ON A FORMULATION WITH HIGH PENETRATION & LOW SYSTEMIC ABSORPTION a SHOW YOUR D E T C E P X E N U SERNIVO ® (betamethasone dipropionate) Spray, 0.05% is a novel, in the epidermis and dermis, . 1,2 hard-to-reach plaques on the back hard-to-treat elbows and knees 3 and hairy areas. • Nearly 75% of plaques on elbows and knees were clear or 5 SP R A Y O N With the , d success versus vehicle at Day 15 (20.3% vs 5%; p <0.001) and Day 29 (38.7% vs 12.6%; p <0.001 [N=538]). 3,b • by approximately 50% 3,c

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - FEB 2018